Managed Care Approach to the Treatment of Neurogenic Orthostatic Hypotension

October 30, 2015



Abstract

Neurogenic orthostatic hypotension (NOH) is an orphan disease that primarily affects patients with neurodegenerative disorders such as Parkinson’s disease and multiple system atrophy. The first step in the management of NOH is to discontinue or minimize the use of drugs that lower blood pressure. Nonpharmacologic therapy for NOH includes physical countermaneuvers, compression abdominal binders and lower extremity stockings, recognition and avoidance of orthostatic stressors, hydration, and salt supplementation. The manage-ment of NOH should also include interventions to prevent falls. Pharmacotherapy for NOH includes the mineralocorticoid drug fludrocortisone to expand plasma volume and the sympathomimetic drugs midodrine and droxidopa. Clinical efficacy, tolerability, and the role of each drug in the treat-ment paradigm are reviewed here.

Am J Manag Care. 2015;21:S258-S268

SUMMARY

NOH is an uncommon disorder with multiple treat-ment considerations. Clinicians often must make use of nonpharmacologic treatments and pharmacotherapy to improve the daily activities and QOL of patients who suffer symptoms of NOH. Until recently, midodrine and fludrocortisone were the mainstays for drug therapy of NOH. The recent approval of droxidopa adds to the clinician’s armamentarium, providing patients with another alternative to treat symptoms of NOH.http://isaac_image2.jpgOrthostatic hypotension (OH) caused by non-neurogenic mechanisms like volume depletion or cardiac failure is common, especially in elderly patients.1,2 In comparison, neurogenic orthostatic hypotension (NOH) is a rare disorder that occurs primarily in patients already given a diagnosis of a degenerative disease such as Parkinson’s disease (PD), diffuse Lewy body disease, pure autonomic failure, or multiple system atrophy (MSA).3 Patients with severe NOH suffer from debilitating symptoms that substantially impair their ability to complete activities of daily living and reduce their quality of life (QOL). Classic NOH symptoms, such as orthostatic dizziness and syn-cope, and less appreciated symptoms, such as coat-hanger pain and cognitive impairment, can force patients to cur-tail activities that involve standing or walking.4

As a rare disease, NOH has unique management challenges with few well-established treatments, and it requires a patient-oriented approach in which nonphar-macologic strategies may be augmented by pharmaco-therapy. In addition, patients with NOH might be treated with drugs for comorbid disorders that exacerbate NOH and, as a result, they are at risk for drug interactions and adverse effects.5-7

Treatment Goals and Plans

The goals of NOH treatment are to reduce symptoms, improve functional ability and QOL, and reduce the occurrence of falls and syncope.7 The associated risks of fractures, trauma, and functional decline make fall prevention an important priority in the management of patients with NOH.8 Considering that this disease reflects degenerative autonomic dysfunction, restoration of normal blood pressure responses is not a realistic treatment goal. Instead, maintaining standing and supine blood pressures within the range of cerebral autoregulation (approximately 90 mm Hg) will aid in reducing symptoms. Approximately half of patients with NOH also suffer from supine hypertension (SH).9 In these patients, an additional goal is to minimize increases in supine blood pressure.

The Figure7,10,11 depicts a treatment algorithm for managing NOH.7 Patients with NOH are often elderly with multiple comorbidities and a high rate of poly-pharmacy.5-7 Therefore, the first step in management is to assess the patient’s treatment regimen for drugs that cause OH.9 A strong emphasis on patient education is necessary to teach patients how to perform physi-cal countermaneuvers and implement other nondrug measures that improve QOL, including minimizing orthostatic stressors. The head of the bed should be maintained at 30 degrees or higher to minimize SH and reduce nocturnal diuresis. Pharmacotherapy is needed for patients who remain symptomatic despite nonpharmacologic interventions. Management options for NOH, through both nonpharmacologic treatment and pharmacotherapy, act by either volume expansion or vasoconstriction (see Table 17,10).7,10

Druginduced Orthostatic Hypotension

Receiving multiple drugs that can cause OH increases the risk of a patient suffering from symp-tomatic OH.5,12 Drug classes commonly linked to causing OH include diuretics, alpha1-antagonists, antidepressants, antipsychotics, levodopa and dopaminergic drugs for PD, and vasodilators (see Table 25,6,13-20).5,12-14 Within drug classes, specific agents may have an especially high risk of causing OH; some of these are listed on the American Geriatric Society Beers Criteria for Potentially Inappropriate Medication Use in Older Adults because they pose a risk for elderly patients in general. Drugs listed on the Beers Criteria because they increase the risk of OH in the elderly include amitriptyline, clomipramine, doxazosin, doxepin over 6 mg/day, imipramine, prazosin, terazosin, and trimipramine.15

In male patients, benign prostatic hypertrophy may be treated with an alpha1-antagonist, leading to exacerbation of OH. Prazosin, which has high affinity to alpha1-receptors and a rapid onset of action, is considered the alpha1-antagonist with the highest risk of causing OH.16 A recent analysis of medical claims data found that even “urospecific” alpha1-antagonists, such as silodosin and tamsulosin, were linked to a higher risk of hip fracture during early use, likely due to OH.21 An increased risk of hospitalization for hypotension has been reported in men soon after starting tamsulosin, with a 2-fold increase in risk during the first month of therapy.22 An analysis of the FDA Adverse Events Reporting System found a signal for most alphaantagonists, with a reporting odds ratio for OH of 2.66 for doxazosin, 3.31 for tamsulosin, 4.21 for alfuzosin, and 6.13 for terazosin.23

Atypical antipsychotic drugs with high alpha1-antagonist activity increase the risk of OH, especially clozapine, iloperidone, and quetiapine. Increased rates of OH have been reported with the low-potency drugs chlorpromazine and thioridazine.14 Volume depletion and autonomic dysfunction are risk factors for developing symptomatic OH with alpha1-antagonists and antipsychotic drugs.14,16 Tricyclic antidepressants can cause OH and increase the risk of falling, with the highest risks identified for amitriptyline, imipramine, and doxepin. Monoamine oxidase inhibitors and trazodone can also cause OH.17

A new class of diabetes drugs, the sodium glucose co-transporter 2 inhibitors (canagliflozin, dapagliflozin, empagliflozin), causes an osmotic diuresis via increased renal excretion of glucose.24 They can cause symp-tomatic hypotension in certain groups of susceptible patients, including patients with impaired renal func-tion, the elderly, patients undergoing coadministration of diuretics, angiotensin-converting enzyme inhibitors, or angiotensin receptor blockers, and those with low systolic blood pressure.25 However, a meta-analysis of clinical trial data did not find a significant risk of OH.24 Considering how important it is for patients with NOH to maintain optimal intravascular volume, it may be pru-dent for them to avoid this class of drugs.

Dopaminergic drugs used to treat motor symptoms of PD can lower blood pressure and may exacerbate NOH. Levodopa can cause reductions in blood pressure in patients who have PD, and higher doses were linked to an increased risk of falls in one study.18,26 Dopamine agonists also commonly cause OH, which can be symp-tomatic.19 Symptomatic OH has also been noted with selegiline and amantadine.6,19

Antihypertensive drugs, particularly diuretics, can cause OH. In epidemiologic studies of patients with PD, diuretics increased the odds of OH by more than 5-fold and the odds of falling by more than 3-fold.6,26 Probably because negative effects on cardiac conduction and contractility prevent a compensatory increase in heart rate when standing, the nondihydropyridine calcium channel blockers diltiazem and verapamil can cause OH.20 Despite the risk of OH with some antihypertensive drugs, maintaining blood pressure control is an important goal because uncontrolled hypertension exacerbates OH and increases the risk of falling.7,27

Physical Countermaneuvers and Patient Education

Physical countermaneuvers that reduce venous pooling are an important strategy patients can use to increase orthostatic tolerance and prevent syncope. These measures include crossing one’s legs while standing, squatting, and tensing muscles in the legs, thighs, and buttocks.28,29 Routine use of leg-crossing in patients with autonomic failure can increase blood pressure by approximately 20/10 mm Hg. Bending forward can also increase orthostatic tolerance; this maneuver lowers the head to heart level and increases cardiac output through abdominal compression.30 Video instructions and tutorials that demonstrate these techniques can be viewed at www.syncopedia.org31 and www.stars.org.uk.32 An important limitation for physical countermaneuvers is that patients who are elderly or debilitated may have difficulty performing them.

In addition to physical countermaneuvers, patients can employ external devices to increase their functionalability. Patients with adequate balance can use folding chairs when they feel lightheaded or have been walking for extended distances.33 In addition, elastic and pull-string abdominal binders can be used to increase standing blood pressure.34,35 Abdominal binders reduce pooling of blood in the splanchnic circulation, a greater contributor to venous pooling than the lower extremities. Thigh-high or waist-high compression stockings that provide at least 15 to 20 mm Hg of compression can also help reduce venous pooling on standing.7 However, abdominal binders and compression stockings can be difficult for patients to put on without assistance.36

Patients with NOH need to learn how to manage activities and conditions that cause orthostatic stress or exacerbate the disease. When they change positions, they should do so slowly to allow time for autonomic adaption. For instance, in going from a supine position to walking, patients should sit before standing and stand for several minutes before walking.37 Large meals, especially those high in carbohydrates and consumed with alcohol, can cause postprandial OH by causing vasodilation in the splanchnic circulation.38 Compared with 3 standard meals, eating 6 small meals has been shown to improve orthostatic symptoms and standing tolerance.35 Exercise, especially with activities that are recumbent or done in water, are encouraged in order to prevent deconditioning, which can exacerbate NOH.7 However, patients should avoid exercising in the morning, when orthostatic symptoms are typically worse.

Patients with NOH must be diligent to maintain intravascular volume because volume depletion can exacer-bate symptoms. The American Society of Hypertension recommends that NOH patients drink 1.5 to 2 L of water daily.7 In addition, they should consume 6 to 10 g of salt daily, taking 1 g of salt (as tablets) with each meal if needed. Drinking 300 to 500 mL of water over 3 to 4 minutes can induce a pressor effect that has an onset within 10 to 15 minutes, peaks at 40 minutes, and can last over an hour.3,10,39 Rapid water drinking induces hypo-osmolality in the portal vein, which triggers a sympathetic reflex. Drinking water is an important option for managing morning symptoms of NOH, as well as postprandial OH. As one expert notes, “Being free, readily available, and highly effective in many patients, water is the first-line ‘drug’ for NOH.”10

Additionally, patients should be advised to elevate the head of the bed at least 30 degrees to lower SH and reduce nocturnal diuresis. This may also improve baroreflex failure. Patients should be encouraged to document blood pressure measurements and orthostatic symptoms in a diary.3 This may be helpful in identifying orthostatic stressors and nondrug strategies to minimize orthostatic symptoms.

Fall Prevention

OH is a major and independent risk factor for falls in elderly patients; in a large study of nursing home resi-dents, OH increased the risk of subsequent falls by 2.6-fold.40 In ambulatory patients who have PD, OH almost doubled the risk of falls (multivariate odds ratio 1.84; 95% CI, 1.02-3.31).26 A high incidence of fractures and trauma caused by falls has been documented in patients with severe NOH due to autonomic failure.41 The CDC has created a comprehensive fall prevention program called Stopping Elderly Accidents, Deaths and Injuries (STEADI) that has the potential to reduce morbidity from falls in patients with OH.42 It includes tools and educational materials for clinicians and an algorithm of fall risk assessment and interventions. One important component of this program is minimizing the use of drugs that increase the risk of a fall, including benzodiazepines and anticholinergic drugs. A practice guideline from the American Geriatric Society recommends that assess-ment and treatment of OH should be part of multifactorial interventions to prevent falls in elderly patients and those of any age who have gait or balance difficulties.43 This recommendation is based on results from 3 random-ized controlled trials that demonstrated a reduction in falls with multifactorial interventions, which included treatment of OH in addition to other interventions, such as medication reduction, optimization of fluids, and behavioral interventions.

Pharmacotherapy of NOH

The primary defect in NOH is the failure of sym-pathetic neurons to release norepinephrine and cause vasoconstriction. This defect is addressed directly by 2 sympathomimetic drugs approved by the FDA for the management of NOH: droxidopa and midodrine. The role of sympathomimetic drugs is to reduce orthostatic symptoms, prevent falls, and improve QOL.9 In addi-tion to sympathomimetic drugs, the mineralocorticoid fludrocortisone, which acts indirectly through volume expansion, is used off-label in NOH.10 Fludrocortisone is also considered for patients who cannot maintain plasma volume with salt and fluids alone or for those who do not get adequate symptom relief from a sympathomimetic drug.7,10 It is also an alternative for initial therapy in patients who do not have SH. Table 37,9,44-50 compares these pharmacotherapy options for NOH.

The presence of SH impacts treatment decisions for NOH (see Figure7,10,11). Uncontrolled SH induces a pressure diuresis that causes volume depletion and worsens orthostatic symptoms in the morning.9,51 Nonpharmacologic measures to manage SH include avoiding the supine posi-tion during the day and raising the head of the bed by 6 to 9 inches (>30 degrees).7 Also important for patients to know is that the increase in blood pressure from rapid water drinking is substantial enough that those with SH should avoid lying down within 2 hours afterward.52

Patients receiving pharmacotherapy for NOH should be advised to raise the head of the bed to minimize the risk of SH and to reduce nocturnal diuresis. For first-line treatment in patients with SH or heart failure, a sympathomimetic drug is preferred over fludro-cortisone. However, measures must still be taken to minimize the risk of SH with droxidopa and midodrine. Sympathomimetic drugs should be given as needed 30 to 45 minutes before patients with NOH intend to be upright.7 These drugs should not be used when patients intend to remain seated or supine. Product labeling for both droxidopa and midodrine includes a black box warning about the risk of SH; because of this risk, these drugs should not be taken at night.44,45 Specifically, the last dose of either drug should be taken at least 3 hours before bed. In addition, supine blood pressure should be monitored after dosage increases.

The 2-part Orthostatic Hypotension Questionnaire (OHQ) is used to assess symptomatic improvement of NOH in clinical trials and may be used to assess the response to pharmacotherapy in clinical practice. The 6-item Orthostatic Hypotension Symptom Assessment (OHSA) asks about dizziness/lightheadedness (OHSA item 1), vision disturbance, weakness, fatigue, trouble con-centrating, and head or neck discomfort. The Orthostatic Hypotension Daily Activity Scale (OHDAS) assesses the interference of NOH with standing and walking. Patients score items on a scale of 0 to 10. An improvement of 0.8 to 1.0 units is considered a minimal important change on the OHSA, OHDAS, and OHQ composite score.53 Ambulatory blood pressure monitoring also has a role in assessing the response to pharmacotherapy.54

Droxidopa

Droxidopa is a synthetic amino acid prodrug that is converted to norepinephrine through decarboxylation by dopa decarboxylase. It was approved by the FDA in 2014 for the treatment of symptomatic NOH caused by primary autonomic failure, dopamine beta-hydroxylase deficiency, and nondiabetic autonomic neuropathy.44 More specifically, it was approved for orthostatic dizziness, lightheadedness, or for when a patient feels as if they may black out, (otherwise known as OHSA item 1). In a single-dose study of patients with NOH, the pressor effect of droxidopa had an onset at 1 hour and peaked 3.5 hours after the dose.47 The duration of action was 6 hours while standing and 8 hours while supine. A high-fat meal reduces peak levels by 35% and delays the time to peak levels by approximately 2 hours. Patients should be counseled to take droxidopa consistently either with or without food to account for this food effect.44

Clinical Efficacy

Droxidopa was evaluated in 3 phase 3 studies (301, 302, 306). Two of these trials (301, 302) enrolled patients with NOH due to PD, pure autonomic failure, MSA, nondiabetic autonomic neuropathy, or dopamine-beta-hydroxylase deficiency.55,56 The third trial (306) enrolled only patients with NOH caused by PD.57,58

Study 302 (the first phase 3 trial performed) had an open-label dose-optimization phase to identify droxi-dopa responders, followed by a 7-day open-label phase in which responders continued droxidopa treatment. Patients were then randomized to a 14-day double-blind withdrawal phase where they received droxidopa or placebo. Droxidopa was not more effective than placebo for the primary end point, OHSA item 1; however, a post hoc analysis found that the mean change in the OHQ composite score was significantly lower with droxidopa than with placebo (0.11 ± 2.18 vs 1.22 ± 2.39; P = .013).56

Study 301 (the second phase 3 trial performed) began with a dose-optimization phase to identify patients who responded to and tolerated droxidopa (n = 263). After a 7-day washout phase, responders received double-blind treatment with droxidopa (n = 82) or placebo (n = 80) for 1 week. The change in composite OHQ score from random-ization to week 1, the primary outcome, was −1.83 for droxi-dopa and −0.93 for placebo (treatment difference of 0.9; 95% CI, 0.30-1.48; P = .003). More patients had an improvement in the composite OHQ score of at least 3 units with droxi-dopa than with placebo (27.2% vs 11.4%; P = .016). Standing blood pressure also improved with droxidopa.55 The results of Study 301 led to a subsequent trial in patients with PD.

In study 306, which was the third phase 3 trial per-formed, patients initially entered a randomized double-blind dose-optimization phase in which they received droxidopa or placebo for up to 2 weeks before entering an 8-week treatment phase.58,59 After a planned interim analysis of the first 51 participants found no significant difference between droxidopa and placebo in the ini-tial primary end point of OHQ composite score, that analysis was designated as study 306a because of poten-tial unblinding. After discussion with the FDA, the pri-mary outcome was switched to a change in OHSA item 1 between baseline and week 1 and the subsequent 171 patients to enter the study were designated as study 306b,which became the pivotal trial supporting FDA approv-al.59 In Study 306b, the mean change in OHSA item 1 from randomization to week 1 was −2.3 for droxidopa and −1.3 for placebo (P <.05).58 Standing supine blood pressure also was significant over placebo at week 1.

Based on pooled data from studies 301 and 306, the number needed to treat (NNT) for at least 50% improve-ment in OSHA item 1 at 1 week was 5 (95% CI, 3-11). The number needed to harm (NNH) for development of hypertension was 28 (95% CI, 16-95). For discontinuation due to an adverse event, the NNH was 34. A response to droxidopa was 6.8 times more likely than an adverse event leading to discontinuation.60

The long-term efficacy of droxidopa has been evaluated in a 1-year open-label extension study (study 303) that enrolled 102 patients from studies 301 and 302. Patients received droxidopa for 3 months and then were randomized to receive droxidopa (n = 38) or placebo (n = 37) for 2 weeks. There was no significant difference between groups in the primary end point, mean change in composite OHQ score from baseline.43 However, after more than 1 year of open-label treatment with droxi-dopa, the changes from baseline in OHSA item 1 and OHQ composite scores were maintained.61,62 Droxidopa has demonstrated efficacy only in studies lasting less than 2 weeks.55,58 Product labeling recommends that patients be evaluated periodically to determine whether they con-tinue to benefit from droxidopa.44

Adverse Effects

The most commonly reported adverse effects with droxidopa in premarketing clinical trials were headache, dizziness, nausea, and hypertension.44 Adverse effects most often leading to discontinuation of droxidopa included hypertension and nausea. In Japan, where drox-idopa has been available since 1989, a symptom complex similar to neuroleptic malignant syndrome has been reported, but rarely.44,59

Drug Interactions

Many patients with PD receive carbidopa, a dopa decarboxylase inhibitor, in order to prevent conversion of levodopa to dopamine in the peripheral nervous system. A high single dose of carbidopa (200 mg) has been shown to inhibit the conversion of droxidopa to norepinephrine and abolish its pressor effect.47 Analysis of clinical trial data has not resolved the question of whether lower doses of carbidopa impair the efficacy of droxidopa.55 Droxidopa product labeling advises that dosage adjustment of droxidopa may be necessary if it is co-administered with carbidopa, and because of concerns about additive effects on SH, the product labeling recommends against co-administration of midodrine.43 Droxidopa has been given with fludrocortisone in some clinical trials; approximately 20% of patients in the droxi-dopa pivotal trials also used fludrocortisone.57,58

Availability

Droxidopa is considered a specialty drug that the manufacturer has made available through a specialty pharmacy distribution network.63 The prescriber and patient must complete prescription forms to obtain the drug. In order for patients to receive a trial of droxidopa, prior authorization procedures may require documenta-tion that the patient has not responded to or tolerated other drugs for NOH.

Midodrine

Midodrine is a direct alpha1-agonist that increases blood pressure by vasoconstriction. It is a prodrug that is metabolized to an active metabolite, desglymidodrine.38 Midodrine acts periph

Clinical Efficacy

In 1996, Shire received fast-track approval from the FDA to market midodrine for symptomatic OH, with 7 years of marketing exclusivity as an orphan drug. Approval was based on studies that demonstrated improvement in a surrogate outcome, 1-minute standing systolic blood pressure. The company agreed to complete additional studies to establish symptomatic efficacy.

In 2003, when marketing exclusivity ended, Shire discontinued the brand name product, leaving only generic products available. In 2010, the FDA proposed withdrawing approval of midodrine because Shire had failed to submit adequate postmarketing studies to establish symptomatic benefit. In 2012, Shire agreed to conduct 2 studies to establish the efficacy of midodrine for relieving OH symptoms.64

These studies have been completed, but not published. Preliminary results have been posted on www.clinicaltrials.gov.65,66 In a placebo-controlled tilt table test, the time to onset of syncope or near-syncope was significantly lon-ger with midodrine (1105.6 vs 1626.6 sec; mean difference 521 sec; 95% CI, 124.2-917.7; P = .0131).65 In a midodrine withdrawal study, 98 patients with severe OH were treat-ed with the midodrine regimen they had taken before the study. Patients were randomized to receive midodrine for 16 days or midodrine for 15 days followed by placebo on the last day. The primary outcome of the study was the percentage of patients who failed to maintain a response 30 minutes after the dose on day 16, with failure defined as either a 4-point increase on OHSA item 1 or an increase in syncopal or near-syncopal events within 15 minutes after standing. The percentage of patients who failed to maintain a response was 30.3% for midodrine and 44.1% for placebo (mean difference of 13.8%; 95% CI, −37.6 to 9.8; P = .3145).66 Patients and clinicians maintain that midodrine may have QOL and symptomatic benefits that the clinical trials have failed to identify.67 An independent systematic review evaluated symp-tom improvement and adverse effects of midodrine in clinical trials of symptomatic OH. There was high het-erogeneity (I2 = 73%) among 5 studies that were included in the analysis. The odds ratio for symptom improvement with midodrine was 3.9 (95% CI, 1.8-8.3), providing an NNT of 3 (95% CI, 2-7).68

Adverse Effects

Adverse effects reported with midodrine are related to its alpha-agonist activity. These include pilo-erection, pruritus (especially on the scalp), paresthesia, urinary reten-tion, and SH.48,69 The previously cited systematic review evaluated adverse effects with midodrine in clinical trials of symptomatic OH.63 The relative risk of a minor adverse event (primarily piloerection, paresthesias, chills, and GI discomfort) was 4.58 (95% CI, 2.03-10.37), providing an NNH of 8 (95% CI, 3-27). Based on data from 3 studies, midodrine increased the risk of SH (relative risk 5.31; 95% CI, 1.39-20.27), with an NNH of 14 (95% CI, 9-50).68 Drug Interactions Because midodrine is a direct alpha1-agonist, its effects are opposed by alpha1-antagonists.45 There is concern that co-administration of midodrine and digoxin or beta-blockers may cause bradycardia. Fludrocortisone Fludrocortisone is a mineralocorticoid that causes volume expansion by increasing renal sodium reabsorption.10 These effects normalize over time, so other mechanisms may be responsible for its effects in NOH. Unlike the sympathomimetic drugs, it has a long duration of action (biologic half-life of 18 to 36 hours).46 In addition, it had equivalent effects on standing and supine blood pressure in a study of patients with OH due to diabetic autonomic neuropathy.70 These properties raise concern about exacerbation of SH.10 Doses of 0.1 to 0.2 mg are suggested, but some patients can respond with up to 0.6 mg daily. Clinical Efficacy Clinical trials provide little evidence for the efficacy of fludrocortisone in NOH. In a double-blind crossover trial, fludrocortisone 0.1 mg twice daily improved orthostatic blood pressure measurements in 5 patients with NOH due to diabetic neuropathy.70,71 Increases in stand-ing blood pressure were reported with fludrocortisone plus head-up sleeping in an observational study of 8 patients with NOH.72 A Movement Disorder Society Task Force found insufficient evidence to evaluate the safety and efficacy of fludrocortisone for OH in PD.73 Adverse Effects Fludrocortisone can cause hypokalemia, pedal edema, SH, and glucocorticoid effects.45 In order to minimize the risk of these adverse effects, the lowest effective dose of fludrocortisone should be used. Weight gain is expected due to fluid retention; therefore, heart failure is a relative contraindication.7 To prevent hypokalemia, potassium levels should be monitored and potassium supplementa-tion provided if needed.

Additional Pharmacotherapy Options

Other drugs have been evaluated for treatment of NOH, but they do not have a well-defined role in management. These include non-steroidal anti-inflamma-tory drugs (primarily indomethacin), erythropoietin in patients with anemia, and desmopressin in patients with nocturnal polyuria.74-76 Octreotide and acarbose have been evaluated for postprandial hypotension.77,78

Atomoxetine inhibits norepinephrine reuptake by inhibiting the pre-synaptic norepinephrine transporter. In patients with NOH due to autonomic failure who have residual sympathetic activity, this has the potential to raise blood pressure by increasing synaptic nor-epinephrine levels.7 Atomoxetine displayed a pressor effect only in patients with central autonomic failure in a study that compared its effects in patients with central and peripheral autonomic failure.79 A placebo-controlled crossover study compared single doses of atomoxetine and midodrine in 65 patients with severe autonomic failure and NOH.80

At 1 minute, upright systolic blood pressure was significantly higher with atomoxetine than midodrine (means difference 7.5 mm Hg; 95% CI, 0.6-15; P = .03). Change in the OHQ total score was significantly greater with atomoxetine than placebo (0.4 points; 95% CI, −0.1 to −0.8; P = .02). The OHQ total score with midodrine was not significantly different from placebo (0.5 points; 95% CI, −0.1 to 1.0; P = .08). Further study is necessary to define the role of atomoxetine in NOH. The cholinesterase inhibitor pyridostigmine may increase standing blood pressure by increasing choliner-gic transmission in the autonomic ganglia.10 A potential advantage of pyridostigmine is that it has demonstrated little potential to cause SH. A randomized controlled trial evaluated a single dose of pyridostigmine alone or in combination with midodrine in 60 patients with NOH.81 It caused a modest increase in standing blood pressure that was associated with symptom improvement. A sur-vey reported moderate to marked symptom improvement in 17 of 20 patients who continued long-term treatment with pyridostigmine after the single-dose study.82 In a sec-ond study of patients with NOH and autonomic failure, pyridostigmine did not improve standing blood pressure or symptoms.83 Cholinergic adverse effects can limit the use of pyridostigmine in NOH.10

Author affiliation: Parkinson’s Disease and Movement Disorders Center of Boca Raton, Florida International University Herbert Wertheim College of Medicine.

Funding source: This activity is supported by an educational grant from Lundbeck, LLC.

Author disclosure: Dr. Isaacson has the following relevant commer-cial financial relationships or affiliations to disclose:

Grant/Research Support: Abbvie, Acadia, Acorda, Adamas, Addex, Amarantus, Auspex, Biotie, Cynapsus, Eisai, GE Healthcare, Ipsen, Kyowa, Lundbeck, Merz, Novartis, Neurocrine, Pfizer, Pharma2B, Roche, Santhera, Serono, Shire, Teva, UCB, US World Meds,

Xenoport Consultant: Acadia, Acorda, Allergan, Amarantus, Auspex, Biotie, Britannia, Cynapsus, Eisai, GE Healthcare, Impax, Ipsen, Kyowa, Lundbeck, Teva, UCB, US World Meds, Xenoport

Speaker’s Bureau: Abbvie, Acadia, Allergan, GE Healthcare, Impax, Lundbeck, Teva, UCB, US World Meds, Xenoport

Authorship information: Concept and design, acquisition of data, analysis and interpretation of data, drafting of the manuscript, and critical revision of the manuscript for important intellectual content.

Address correspondence to: isaacson@ParkinsonsCenter.org.1. Goldstein DS, Sharabi Y. Neurogenic orthostatic hypotension: a pathophysiological approach. Circulation. 2009;119(1):139-146.

2. Arnold AC, Shibao C. Current concepts in orthostatic hypoten-sion management. Curr Hypertens Rep. 2013;15(4):304-312.

3. Freeman R. Clinical practice. Neurogenic orthostatic hypoten-sion. N Engl J Med. 2008;358(6):615-624.

4. Low PA, Opfer-Gehrking TL, McPhee BR, et al. Prospective evaluation of clinical characteristics of orthostatic hypotension. Mayo Clin Proc. 1995;70(7):617-622.

5. Poon IO, Braun U. High prevalence of orthostatic hypotension and its correlation with potentially causative medications among elderly veterans. J Clin Pharm Ther. 2005;30(2):173-178.

6. Perez-Lloret S, Rey MV, Fabre N, et al. Factors related to orthostatic hypotension in Parkinson’s disease. Parkinsonism Relat Disord. 2012;18(5):501-505.

7. Shibao C, Lipsitz LA, Biaggioni I. Evaluation and treatment of orthostatic hypotension. J Am Soc Hypertens. 2013;7(4):317-324.

8. Maule S, Milazzo V, Maule MM, Di Stefano C, Milan A, Veglio F. Mortality and prognosis in patients with neurogenic orthostatic hypotension. Funct Neurol. 2012;27(2):101-106.

9. Biaggioni I. Treatment: special conditions: orthostatic hypoten-sion. J Am Soc Hypertens. 2015;9(1):67-69; quiz 70.

10. Schroeder C, Jordan J, Kaufmann H. Management of neuro-genic orthostatic hypotension in patients with autonomic failure. Drugs. 2013;73(12):1267-1279.

11. Jordan J, Shannon JR, Biaggioni I, Norman R, Black BK, Robertson D. Contrasting actions of pressor agents in severe autonomic failure. Am J Med. 1998;105(2):116—24.

12. Kamaruzzaman S, Watt H, Carson C, Ebrahim S. The asso-ciation between orthostatic hypotension and medication use in the British Women’s Heart and Health Study. Age Aging. 2010;39(1):51-56.

13. Milazzo V, Stefano CD, Servo S, et al. Drugs and orthostatic hypotension: evidence from literature. J Hypertens. 2012;1(2):1-8.

14. Gugger JJ. Antipsychotic pharmacotherapy and orthostatic hypotension: identification and management. CNS Drugs. 2011;25(8):659-671.

15. American Geriatrics Society updated Beers Criteria for poten-tially inappropriate medication use in older adults. J Am Geriatr Soc. 2012;60(4):616-631.

16. Sica DA. Alpha1-adrenergic blockers: current usage consider-ations. J Clin Hypertens (Greenwich). 2005;7(12):757-762.

17. American Psychiatric Association practice guidelines. American Psychiatric Association website. http://www.psychiatry-online.org/guidelines. Accessed June 19, 2015.

18. Noack C, Schroeder C, Heusser K, Lipp A. Cardiovascular effects of levodopa in Parkinson’s disease. Parkinsonism Relat Disord. 2014;20(8):815-818.

19. Pahwa R, Factor SA, Lyons KE, et al. Practice parameter: treat-ment of Parkinson disease with motor fluctuations and dyskinesia (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2006;66(7):983-995.

20. Milazzo V, Di Stefano C, Servo S, et al. Drugs and orthostatic hypotension: evidence from literature. J Hypertens. 2012;1(2):1-8.

21. Seo GH, Lee YK, Ha YC. Risk of hip fractures in men with alpha-blockers: a nationwide study base on claim registry. J Bone Metab. 2015;22(1):29-32.

22. Bird ST, Delaney JA, Brophy JM, Etminan M, Skeldon SC,Hartzema AG. Tamsulosin treatment for benign prostatic hyper-plasia and risk of severe hypotension in men aged 40-85 years in the United States: risk window analyses using between and within patient methodology. BMJ. 2013;347:f6320.

23. Yoshimura K, Kadoyama K, Sakaeda T, Sugino Y, Ogawa O, Okuno Y. A survey of the FAERS database concerning the adverse event profiles of alpha1-adrenoreceptor blockers for lower urinary tract symptoms. Int J Med Sci. 2013;10(7):864-869.

24. Baker WL, Smyth LR, Riche DM, Bourret EM, Chamberlin KW, White WB. Effects of sodium-glucose co-transporter 2 inhibitors on blood pressure: a systematic review and meta-analysis. J Am Soc Hypertens. 2014;8(4):262-275.e269.

25. Invokana [package insert]. Titusville, NJ: Janssen Pharmaceuticals, Inc; 2015.

26. Rascol O, Perez-Lloret S, Damier P, et al. Falls in ambula-tory non-demented patients with Parkinson’s disease. J Neural Transm. 2015.

27. Gangavati A, Hajjar I, Quach L, et al. Hypertension, orthostatic hypotension, and the risk of falls in a community-dwelling elderly population: the maintenance of balance, independent living, intellect, and zest in the elderly of Boston study. J Am Geriatr Soc. 2011;59(3):383-389.

28. Krediet CT, Go-Schon IK, van Lieshout JJ, Wieling W. Optimizing squatting as a physical maneuver to prevent vasova-gal syncope. Clin Auton Res. 2008;18(4):179-186.

29. Krediet CT, van Dijk N, Linzer M, van Lieshout JJ, Wieling W. Management of vasovagal syncope: controlling or abort-ing faints by leg crossing and muscle tensing. Circulation. 2002;106(13):1684-1689.

30. Wieling W, van Dijk N, Thijs RD, de Lange FJ, Krediet CT, Halliwill JR. Physical countermeasures to increase orthostatic tol-erance. J Intern Med. 2015;277(1):69-82.

. http://syncopedia.org/wiki/Main_Page.

31. de Lang FJ, de Jong J, Wieling W. SYNCOpedia.org website Accessed July 22, 2015.

http://www.stars.org.uk/

32. Syncope trust and reflex anoxic seizures (STARS). STARS website.. Accessed July 22, 2015

33. Smit AA, Wieling W, Opfer-Gehrking TL, van Emmerik-Levelt HM, Low PA. Patients’ choice of portable folding chairs to reduce symptoms of orthostatic hypotension. Clin Auton Res. 1999;9(6):341-344.

34. Figueroa JJ, Singer W, Sandroni P, et al. Effects of patient-controlled abdominal compression on standing systolic blood pressure in adults with orthostatic hypotension. Arch Phys Med Rehabil. 2015;96(3):505-510.

35. Mills PB, Fung CK, Travlos A, Krassioukov A. Nonpharmacologic management of orthostatic hypotension: a systematic review. Arch Phys Med Rehabil. 2015;96(2):366-375.e366.

36. Raj SR, Coffin ST. Medical therapy and physical maneuvers in the treatment of the vasovagal syncope and orthostatic hypoten-sion. Prog Cardiovasc Dis. 2013;55(4):425-433.

37. Isaacson SH, Skettini J. Neurogenic orthostatic hypotension in Parkinson’s disease: evaluation, management, and emerging role of droxidopa. Vasc Health Risk Manag. 2014;10:169-176.

38. Lahrmann H, Cortelli P, Hilz M, et al. Orthostatic hypotension. In: European Handbook of Neurological Management. Oxford, England: Wiley-Blackwell; 2010:469-475.

39. Mathias CJ, Young TM. Water drinking in the management of orthostatic intolerance due to orthostatic hypotension, vasovagal syncope and the postural tachycardia syndrome. Eur J Neurol. 2004;11(9):613-619.

40. Ooi WL, Hossain M, Lipsitz LA. The association between ortho-static hypotension and recurrent falls in nursing home residents. Am J Med. 2000;108(2):106-111.

41. Pathak A, Lapeyre-Mestre M, Montastruc JL, Senard JM. Heat-related morbidity in patients with orthostatic hypotension and pri-mary autonomic failure. Mov Disord. 2005;20(9):1213-1219.

42. STEADI - Older Adult Fall Prevention: make STEADI part of your medical practice. CDC website. http://www.cdc.gov/steadi/ index.html. Accessed June 19, 2015.

43. Panel on Prevention of Falls in Older Persons, American Geriatrics Society and British Geriatrics Society. Summary of the Updated American Geriatrics Society/British Geriatrics Society clinical practice guideline for prevention of falls in older persons. J Am Geriatr Soc. 2011;59(1):148-157.

44. Northera [package insert]. Charlotte, NC: Chelsea Therapeutics, Inc. 2014.

45. Midodrine hydrochloride tablets [package insert]. Weston, FL: Apotex Corp. 2011.

46. Fludrocortisone acetate tablets [package insert]. Summerville, PA: Teva Pharmaceuticals. 2011.

47. Kaufmann H, Saadia D, Voustianiouk A, et al. Norepinephrine precursor therapy in neurogenic orthostatic hypotension. Circulation. 2003;108(6):724-728.

48. Wright RA, Kaufmann HC, Perera R, et al. A double-blind, dose-response study of midodrine in neurogenic orthostatic hypo-tension. Neurology. 1998;51(1):120-124.

49. Droxidopa (Northera) for neurogenic orthostatic hypotension. Med Lett Drugs Ther. 2015;57(1471):92-93.

http://www.micromedexso-lutions.pacificlib.idm.oclc.org/.

50. Micromedex 2.0 (electronic version). Truven Health Analytics, Grewwnwood Village, Colorado, USA. Accessed Sepember 29, 2015.

51. Freeman R, Wieling W, Axelrod FB, et al. Consensus statement on the definition of orthostatic hypotension, neurally mediated syncope and the postural tachycardia syndrome. Clin Auton Res. 2011;21(2):69-72.

52. Adis Medical Writers. Consider pharmacotherapy for neuro-genic orthostatic hypotension only if non-pharmacological mea-sures fail. Drugs & Therapy Perspectives. 2014;30(4):135-140.

53. Kaufmann H, Malamut R, Norcliffe-Kaufmann L, Rosa K, Freeman R. The Orthostatic Hypotension Questionnaire (OHQ): validation of a novel symptom assessment scale. Clin Auton Res. 2012;22(2):79-90.

54. Brillman S, Husain S, Isaacson SH. Long-term evaluation of 24 hour ambulatory blood pressure monitoring in patients with Parkinson’s disease and symptomatic neurogenic orthostatic hypotension treated with droxidopa [abstract 188]. Mov Disord. 2015;30(suppl 1):S72-S73.

55. Kaufmann H, Freeman R, Biaggioni I, et al; NOH301 Investigators. Droxidopa for neurogenic orthostatic hypoten-sion: a randomized, placebo-controlled, phase 3 trial. Neurology. 2014;83(4):328-335.

56. Biaggioni I, Freeman R, Mathias CJ, Low P, Hewitt LA, Kaufmann H. Randomized withdrawal study of patients with symptomatic neurogenic orthostatic hypotension responsive to droxidopa. Hypertension. 2015;65(1):101-107.

57. Hauser RA, Hewitt LA, Isaacson S. Droxidopa in patients with neurogenic orthostatic hypotension associated with Parkinson’s disease (NOH306A). J Parkinsons Dis. 2014;4(1):57-65.

58. Hauser RA, Isaacson S, Lisk JP, Hewitt LA, Rowse G. Droxidopa for the short-term treatment of symptomatic neuro-genic orthostatic hypotension in Parkinson’s disease (nOH306B). Mov Disord. 2015;30(5):646-654.

59. Keating GM. Droxidopa: a review of its use in symptomatic neurogenic orthostatic hypotension. Drugs. 2015;75(2):197-206.

60. Francois C, Rowse GJ, Hauser RA, Hewitt LA. Number-needed-to-treat analysis of droxidopa in patients with symptomatic neu-rogenic hypertension [abstract 222]. Mov Disord. 2015;30(suppl 1):S86.

61. Isaacson S, Liang G, Lisk JP, Rowse GJ. Durability of effect with long-term droxidopa treatment in patients with symptomatic NOH [abstract 239]. Mov Disord. 2015;30(suppl 1):S93.

62. Isaacson S, Shill H, Vernino S, Cioffi C, Hutchman R. Durability of effect with longterm, open-label droxidopa treatment in patients with symptomatic neurogenic orthostatic hypoten-sion (NOH 303) [abstract 1291]. Mov Disord. 2012;27(suppl 1):S424-S425.

63. Lundbeck NA Ltd. NORTHERA Support Center website. https:// www.northera.com/support-center. Accessed June 22, 2015.

64. Mitka M. Trials to address efficacy of midodrine 18 years after it gains FDA approval. JAMA. 2012;307(11):1124, 1127.

65. Shire Pharmaceuticals. Tilt-table study of the clinical efficacy of midodrine in symptomatic orthostatic hypotension. Clinicaltrials.gov website. https://clinicaltrials.gov/ct2/show/NCT01518946. Updated October 10, 2014. Accessed June 17, 2015.

66. Shire Pharmaceuticals. Clinical efficacy of midodrine in symptomatic orthostatic hypotension. Clinicaltrials.gov website. https:// www.clinicaltrials.gov/ct2/show/results/NCT01515865?sect=X701 56&term=midodrine&rank=12#outcome1. Updated November 10, 2014. Accessed June 17, 2015.

67. Dysautonomia International. RE: Docket ID: FDA-2012-N-0967-0595. http://www.dysautonomiainternational.org/pdf/ Dysautonomia_International_Comment_12.3.14.pdf. Published December 3, 2014. Accessed June 17, 2015.

68. Izcovich A, Gonzalez Malla C, Manzotti M, Catalano HN, Guyatt G. Midodrine for orthostatic hypotension and recurrent reflex syncope: a systematic review. Neurology. 2014;83(13):1170-1177.

69. Low PA, Gilden JL, Freeman R, Sheng KN, McElligott MA. Efficacy of midodrine vs placebo in neurogenic orthostatic hypo-tension. A randomized, double-blind multicenter study. Midodrine Study Group. JAMA. 1997;277(13):1046-1051.

70. Campbell IW, Ewing DJ, Clarke BF. 9-Alpha-fluorohydrocortisone in the treatment of postural hypotension in diabetic autonomic neuropathy. Diabetes. 1975;24(4):381-384.

71. Ong AC, Myint PK, Shepstone L, Potter JF. A systematic review of the pharmacological management of orthostatic hypo-tension. Int J Clin Pract. 2013;67(7):633-646.

72. van Lieshout JJ, ten Harkel AD, Wieling W. Fludrocortisone and sleeping in the head-up position limit the postural decrease in car-diac output in autonomic failure. Clin Auton Res. 2000;10(1):35-42.

73. Seppi K, Weintraub D, Coelho M, et al. The Movement Disorder Society Evidence-Based Medicine Review Update: treat-ments for the non-motor symptoms of Parkinson’s disease. Mov Disord. 2011;26(suppl 3):S42-S80.

74. Abate G, Polimeni RM, Cuccurullo F, Puddu P, Lenzi S. Effects of indomethacin on postural hypotension in Parkinsonism. Br Med J. 1979;2(6203):1466-1468.

75. Winkler AS, Landau S, Watkins PJ. Erythropoietin treatment of postural hypotension in anemic type 1 diabetic patients with auto-nomic neuropathy: a case study of four patients. Diabetes Care. 2001;24(6):1121-1123.

76. Mathias CJ, Fosbraey P, da Costa DF, Thornley A, Bannister R. The effect of desmopressin on nocturnal polyuria, overnight weight loss, and morning postural hypotension in patients with autonomic failure. Br Med J (Clin Res Ed). 1986;293(6543):353-354.

77. Bordet R, Benhadjali J, Destee A, Belabbas A, Libersa C. Octreotide effects on orthostatic hypotension in patients with mul-tiple system atrophy: a controlled study of acute administration. Clin Neuropharmacol. 1995;18(1):83-89.

78. Shibao C, Gamboa A, Diedrich A, et al. Acarbose, an alpha-glucosidase inhibitor, attenuates postprandial hypotension in autonomic failure. Hypertension. 2007;50(1):54-61.

79. Shibao C, Raj SR, Gamboa A, et al. Norepinephrine transporter blockade with atomoxetine induces hypertension in patients with impaired autonomic function. Hypertension. 2007;50(1):47-53.

80. Ramirez CE, Okamoto LE, Arnold AC, et al. Efficacy of atomox-etine versus midodrine for the treatment of orthostatic hypoten-sion in autonomic failure. Hypertension. 2014;64(6):1235-1240.

81. Singer W, Sandroni P, Opfer-Gehrking TL, et al. Pyridostigmine treatment trial in neurogenic orthostatic hypoten-sion. Arch Neurol. 2006;63(4):513-518.

82. Sandroni P, Opfer-Gehrking TL, Singer W, Low PA. Pyridostigmine for treatment of neurogenic orthostatic hypoten-sion [correction of hypertension]--a follow-up survey study. Clin Auton Res. 2005;15(1):51-53.

83. Shibao C, Okamoto LE, Gamboa A, et al. Comparative effi-cacy of yohimbine against pyridostigmine for the treatment of orthostatic hypotension in autonomic failure. Hypertension. 2010;56(5):847-851.